Literature DB >> 20026049

PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities.

Majambu Mbikay1, Francine Sirois, Janice Mayne, Gen-Sheng Wang, Andrew Chen, Thilina Dewpura, Annik Prat, Nabil G Seidah, Michel Chretien, Fraser W Scott.   

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9), a liver-secreted plasma enzyme, restricts hepatic uptake of low-density lipoprotein (LDL) cholesterol by promoting the degradation of LDL receptors (LDLR). PCSK9 and LDLR are also expressed in insulin-producing pancreatic islet beta cells, possibly affecting the function of these cells. Here we show that, compared to control mice, PCSK9-null male mice over 4 months of age carried more LDLR and less insulin in their pancreas; they were hypoinsulinemic, hyperglycemic and glucose-intolerant; their islets exhibited signs of malformation, apoptosis and inflammation. Collectively, these observations suggest that PCSK9 may be necessary for the normal function of pancreatic islets. Copyright 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20026049     DOI: 10.1016/j.febslet.2009.12.018

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  50 in total

Review 1.  Lipid lowering with PCSK9 inhibitors.

Authors:  Razvan T Dadu; Christie M Ballantyne
Journal:  Nat Rev Cardiol       Date:  2014-06-24       Impact factor: 32.419

2.  Proprotein convertase subtilisin/kexin type 7 (PCSK7) is essential for the zebrafish development and bioavailability of transforming growth factor β1a (TGFβ1a).

Authors:  Hannu Turpeinen; Anna Oksanen; Virpi Kivinen; Sampo Kukkurainen; Annemari Uusimäki; Mika Rämet; Mataleena Parikka; Vesa P Hytönen; Matti Nykter; Marko Pesu
Journal:  J Biol Chem       Date:  2013-10-31       Impact factor: 5.157

3.  PCSK9 regulates apoptosis in human neuroglioma u251 cells via mitochondrial signaling pathways.

Authors:  Ming-Xue Piao; Ji-Wei Bai; Peng-Fei Zhang; Ya-Zhuo Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

4.  The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis.

Authors:  Amélie Bonnefond; Loïc Yengo; Cédric Le May; Fréderic Fumeron; Michel Marre; Beverley Balkau; Guillaume Charpentier; Sylvia Franc; Philippe Froguel; Bertrand Cariou
Journal:  Diabetologia       Date:  2015-06-07       Impact factor: 10.122

Review 5.  Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.

Authors:  Giuseppe Danilo Norata; Hagai Tavori; Angela Pirillo; Sergio Fazio; Alberico L Catapano
Journal:  Cardiovasc Res       Date:  2016-08-05       Impact factor: 10.787

Review 6.  The promise of proprotein convertase subtilisin/kexin 9 inhibitors for the treatment of familial hypercholesterolemia.

Authors:  Yashashwi Pokharel; Salim S Virani; Christie M Ballantyne
Journal:  Curr Atheroscler Rep       Date:  2015-05       Impact factor: 5.113

7.  PCSK9 regulates apoptosis in human lung adenocarcinoma A549 cells via endoplasmic reticulum stress and mitochondrial signaling pathways.

Authors:  Xiaohui Xu; Yushang Cui; Lei Cao; Ye Zhang; Yan Yin; Xue Hu
Journal:  Exp Ther Med       Date:  2017-03-10       Impact factor: 2.447

Review 8.  Lysine acetylation in the lumen of the ER: a novel and essential function under the control of the UPR.

Authors:  Mariana Pehar; Luigi Puglielli
Journal:  Biochim Biophys Acta       Date:  2012-12-13

9.  PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice.

Authors:  Anna Roubtsova; Ann Chamberland; Jadwiga Marcinkiewicz; Rachid Essalmani; Ali Fazel; John J Bergeron; Nabil G Seidah; Annik Prat
Journal:  J Lipid Res       Date:  2015-08-31       Impact factor: 5.922

Review 10.  PCSK9 Inhibitors: potential in cardiovascular therapeutics.

Authors:  Rose Q Do; Robert A Vogel; Gregory G Schwartz
Journal:  Curr Cardiol Rep       Date:  2013-03       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.